Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Saved in:
| Title: | Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. |
|---|---|
| Authors: | Shemesh CS; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Chan P; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Shao H; Safety Science, F. Hoffmann-La Roche Ltd., Beijing, China., Xu DZ; Product Development Oncology, F. Hoffmann-La Roche Ltd., Shanghai, China., Combs D; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Vadhavkar S; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Bruno R; Clinical Pharmacology, Genentech-Roche, Marseille, France., Wu B; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA. |
| Source: | Liver cancer [Liver Cancer] 2021 Jun 10; Vol. 10 (5), pp. 485-499. Date of Electronic Publication: 2021 Jun 10 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34721510 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Shemesh+CS%22">Shemesh CS</searchLink>; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Chan+P%22">Chan P</searchLink>; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Shao+H%22">Shao H</searchLink>; Safety Science, F. Hoffmann-La Roche Ltd., Beijing, China.<br /><searchLink fieldCode="AU" term="%22Xu+DZ%22">Xu DZ</searchLink>; Product Development Oncology, F. Hoffmann-La Roche Ltd., Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Combs+D%22">Combs D</searchLink>; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Vadhavkar+S%22">Vadhavkar S</searchLink>; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Bruno+R%22">Bruno R</searchLink>; Clinical Pharmacology, Genentech-Roche, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Wu+B%22">Wu B</searchLink>; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101597993%22">Liver cancer</searchLink> [Liver Cancer] 2021 Jun 10; Vol. 10 (5), pp. 485-499. <i>Date of Electronic Publication: </i>2021 Jun 10 (<i>Print Publication: </i>2021). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22S%2E+Karger%22">S. Karger </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101597993 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2235-1795 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216645553%22">16645553 </searchLink><i>NLM ISO Abbreviation: </i>Liver Cancer <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34721510 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1159/000515817 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 485 Titles: – TitleFull: Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Shemesh CS – PersonEntity: Name: NameFull: Chan P – PersonEntity: Name: NameFull: Shao H – PersonEntity: Name: NameFull: Xu DZ – PersonEntity: Name: NameFull: Combs D – PersonEntity: Name: NameFull: Vadhavkar S – PersonEntity: Name: NameFull: Bruno R – PersonEntity: Name: NameFull: Wu B IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 06 Text: 2021 Jun 10 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 2235-1795 Numbering: – Type: volume Value: 10 – Type: issue Value: 5 Titles: – TitleFull: Liver cancer Type: main |
| ResultId | 1 |
